Nurix enrols the first patient in a Phase 3 designed to demonstrate bexobrutideg's superiority over pirtobrutinib

Nurix Therapeutics said on 4 August 2026 that the first patient has been enrolled in DAYBreak CLL-306, a registrational Phase 3 of its oral BTK degrader bexobrutideg in relapsed/refractory CLL/SLL ^[1], corroborated at headline level by trade press the same day ^[9] — and the design is not the usual one. The trial is described as built to demonstrate superiority of bexobrutideg over pirtobrutinib in patients previously treated with a covalent BTK inhibitor ^[1]. Not non-inferiority. Not a single-arm cohort measured against a historical benchmark. A randomized head-to-head against pirtobrutinib, the registry-listed active comparator, in patients already treated with a covalent BTK inhibitor ^[2].

The release names the trial's registry record: NCT07516093 ^[1]. That record — Phase 3, NX-5948 versus pirtobrutinib, relapsed/refractory CLL/SLL after prior covalent BTK inhibitor treatment, Nurix as sponsor — lists 620 planned participants, progression-free survival assessed by an independent review committee as the primary endpoint, and primary completion in October 2029 ^[2].

What happened, and what sits behind it

Nurix runs the DAYBreak programme on two tracks. The first patients in the registrational programme were dosed in the Phase 2, DAYBreak CLL-201, during the fourth quarter of 2025 ^[4]. That study — NCT07221500, recruiting — is single-arm, 100 patients, in people who have progressed after a covalent BTK inhibitor, a non-covalent BTK inhibitor and a BCL-2 inhibitor; the primary outcome is objective response rate excluding partial response with lymphocytosis, judged by an independent review committee, with a start date of 15 October 2025 and primary completion in January 2028 ^[3][4]. Nurix's J.P. Morgan presentation describes it as "designed to support Accelerated Approval" ^[5]. That is the only regulatory pathway named in the sources reviewed, and it converts to one date: the accelerated-approval-directed dataset is not scheduled to mature before January 2028 ^[3][5]. No submission date, no target action date and no expedited designation in CLL/SLL appears in the records Prognyx reviewed, so no decision window can be derived beyond that anchor.

The second track is CLL-306, and it is a different bet entirely. The clinical basis is the Phase 1a/1b study NX-5948-301, updated at the 67th ASH Annual Meeting in 2025 and reported in Nurix's own results release: in the Phase 1a relapsed/refractory CLL cohort, an objective response rate of 83.0% including two complete responses, median progression-free survival of 22.1 months and median duration of response of 20.1 months across all doses tested ^[4]. The randomized Phase 1b comparison of 200 mg against 600 mg once daily showed higher response rates and a favourable trend toward longer progression-free survival at 600 mg, which became the recommended Phase 2 dose under FDA's Project Optimus with stated alignment from global regulators ^[4]. Safety, as the company describes it: well tolerated across dose levels, no dose-limiting toxicities, no systemic fungal infections, no Grade 4 infections ^[4]. In Waldenström macroglobulinemia, a 75.0% objective response rate with three very good partial responses, and neither median duration of response nor median progression-free survival reached at a median follow-up of 8.1 months ^[4].

Why superiority is the whole story

Nurix did not choose non-inferiority: the release describes CLL-306 as designed to demonstrate superiority ^[1]. It is running a single-arm response-rate study in parallel — but in a narrower, triple-exposed population, after a covalent BTK inhibitor, a non-covalent BTK inhibitor and a BCL-2 inhibitor, not in the CLL-306 population ^[3]. The mechanistic claim the Phase 3 rests on is the company's own: bexobrutideg catalytically degrades the BTK protein, removing both kinase and scaffolding function, which Nurix says enables deeper and more durable pathway suppression at low free-plasma concentrations and broad activity across resistance mutations that limit covalent and non-covalent BTK inhibitors ^[4]. That is a company characterisation, not an independent finding.

What makes CLL-306 consequential beyond Nurix is that it converts a mechanistic argument into a single comparative number. If 620 randomized patients produce a progression-free survival advantage adjudicated by an independent committee, the sequencing question for post-covalent-BTKi CLL is settled by data rather than by class narrative — and every company whose registrational package is a single-arm response-rate cohort will be asked why it did not run the harder trial. If it misses, degradation does not stop working; it stops being obviously better, and the premium the class carries has to be re-argued.

Who is exposed — by name

The registry shows Nurix is not alone in choosing pirtobrutinib as the thing to beat. BeOne Medicines is running NCT06973187, a recruiting Phase 3 of its BTK degrader BGB-16673 compared with pirtobrutinib in adults with relapsed/refractory CLL or SLL — the closest structural mirror of CLL-306 in the record, though the records Prognyx reviewed give its sponsor, phase, recruiting status, comparator and indication but not its eligibility criteria, so whether it draws on the same post-covalent-BTKi pool cannot be determined ^[13]. Newave Pharmaceutical is running ROCKET-CLL, NCT07342478, a recruiting global Phase 3 of rocbrutinib versus pirtobrutinib in covalent-BTKi-pretreated relapsed/refractory CLL/SLL ^[14]. Three sponsors, one comparator. CLL-306 and ROCKET-CLL are registry-stated in the same covalent-BTKi-pretreated population ^[1][2][14]. Enrolment, not statistics, is the first constraint any of them will hit.

BeOne's wider position compounds it: NCT06970743, a Phase 3 of BGB-16673 against investigator's choice of bendamustine, rituximab and methylprednisolone, is active but no longer recruiting, and its dose-escalation and expansion study NCT05006716 is still recruiting, with a China-specific Phase 1/2 of the same degrader run by BeiGene as NCT05294731 ^[15][16][17].

Behind the three head-to-heads sit earlier-phase programmes aimed at the same relapsed or refractory patients: Accutar Biotechnology's AC676, Phase 1 in relapsed/refractory B-cell malignancies ^[18]; AbbVie's ABBV-101 with venetoclax, Phase 1 in B-cell malignancies ^[19]; Merck's nemtabrutinib through ArQule, Phase 1/2 in relapsed or refractory haematologic malignancies ^[20]; Lomond Therapeutics' lonitoclax, Phase 1 in relapsed or refractory B-cell malignancies ^[28]; Guangzhou Lupeng's rocbrutinib with lacutoclax, Phase 1/2 in B-cell malignancies ^[29]; AstraZeneca's Phase 2 of mutation-guided finite acalabrutinib plus venetoclax in relapsed CLL after first-line finite covalent BTKi and BCL-2 inhibitor ^[21]; Curis's Phase 2 of emavusertib with zanubrutinib in CLL and other B-cell malignancies ^[25]; and Ascentage Pharma's Phase 3 of lisaftoclax with a BTK inhibitor in CLL/SLL, line of therapy not stated in the record ^[23]. Also in the record but outside the post-covalent-BTKi setting: Genentech's Phase 2 of venetoclax in first-line patients receiving a covalent BTK inhibitor ^[24], BeiGene's Phase 3 of zanubrutinib in previously untreated CLL/SLL ^[27] and Janssen's long-term extension of ibrutinib ^[26]. Acerta Pharma's Phase 1/2 study of acalabrutinib in CLL, Richter's syndrome or prolymphocytic leukaemia is active but no longer recruiting, and the records Prognyx reviewed do not state its line of therapy ^[22]. These are registry listings: they state what each sponsor is testing, never how well any of it works.

The counterweight in the literature

Degradation is not axiomatically resistance-proof. A Cancer Discovery paper published on 22 July 2026, "Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors", states that early-phase trials of BTK degraders have shown efficacy in BTK-inhibitor-resistant CLL, that how clinical resistance to BTK degraders arises is unknown, and that the authors sequenced serial CLL samples from patients enrolled in the phase I trials ^[7]. The title is a claim to have established that basis; the abstract available to Prognyx is truncated, so no frequency, genotype or cross-resistance finding can be reported here — but a named, previously uncharacterised pan-resistance phenomenon is the single most consequential scientific risk to a superiority hypothesis built on resistance-mutation coverage. A June 2026 review in Journal of Hematology & Oncology holds the other side: covalent and non-covalent BTK inhibitors have extended benefit into relapsed/refractory and BTKi-resistant disease, and an unmet need for further B-cell receptor pathway therapies remains ^[8].

Then the money. Nurix reported $592.9 million in cash and marketable securities for the fiscal quarter ended 30 November 2025 and called itself well capitalised; the J.P. Morgan deck states operations funded into 2028 ^[4][5]. That is the most recent position in the records Prognyx reviewed, and it is eight months old — later quarterly filings were not among them. CLL-306's primary completion is listed for October 2029 ^[2]. On the record as it stands, how a 620-patient Phase 3 is funded past a stated runway is a question those filings do not answer.

What Prognyx could not verify

The registry snapshot available is dated 8 April 2026 and predates the announcement; the status it shows should not be read as current ^[1][2]. No FDA record, label or approval letter establishes pirtobrutinib's regulatory status, indication or mechanistic class ^[1][2]. The records Prognyx reviewed do not carry the eligibility criteria of BeOne's NCT06973187, so its prior-therapy requirements are unknown, not absent ^[13]. CLL-306's randomisation ratio, bexobrutideg dose, stratification, crossover provisions, secondary endpoints, interim plan and the target hazard ratio and power behind "superiority" are absent from the sources reviewed. Whether CLL-306 is the confirmatory trial for a CLL-201 accelerated approval, or an independent path, is not established ^[3][5]. No pirtobrutinib benchmark in post-covalent-BTKi CLL appears in these records, so the 22.1-month figure cannot be set against it. No cash position later than 30 November 2025 was in the records Prognyx reviewed; a subsequent quarterly filing may have superseded the $592.9 million figure and the into-2028 runway statement ^[4][5]. A Roche collaboration on bexobrutideg appears only as an aggregator headline dated 8 June 2026, unconfirmed in the primary sources reviewed ^[12]; the January 2026 filing and the ASH 2025 pipeline slide name Gilead only as the partner on the IRAK4 degrader NX-0479/GS-6791, and name no partner at all on bexobrutideg ^[4][6]. An EMA orphan designation in Waldenström macroglobulinemia rests on a single 8 July 2025 headline, with no EMA or EU register entry in the sources reviewed ^[11]. The Phase 1 efficacy numbers trace to a corporate filing, not to a peer-reviewed paper ^[4][10].

What to watch, with dates

A refreshed NCT07516093 record: an updated recruitment status and an amended start date against the June 2026 listing, which the 8 April 2026 snapshot predates ^[2]. DAYBreak CLL-201's primary completion in January 2028 — the accelerated-approval-directed response-rate dataset ^[3][5]. DAYBreak CLL-306's primary completion in October 2029 ^[2]. Recruitment status changes at NCT07342478, the competing Phase 3 registry-stated in the same covalent-BTKi-pretreated pool ^[14], and at NCT06973187, which shares the comparator and the relapsed/refractory CLL/SLL indication ^[13]. And any Nurix filing that puts financing or partnership terms behind a trial whose readout is a year past the stated runway ^[4][5].

The now-what

One. If you hold a post-covalent-BTKi asset, decide now whether your registrational package is a single-arm response rate or a randomized progression-free survival comparison. Nurix is running both at once — speed through CLL-201, displacement through CLL-306 ^[3][5][1]. With BeOne and Newave also randomizing against pirtobrutinib, a single-arm-only strategy will read as the cheap option in front of a payer ^[13][14].

Two. Treat enrolment as a binding constraint. CLL-306 and Newave's ROCKET-CLL are registry-stated in the same covalent-BTKi-pretreated population ^[1][2][14]; BeOne's NCT06973187 shares the comparator and the relapsed/refractory CLL/SLL indication, and the records Prognyx reviewed do not carry its eligibility criteria, so whether it draws on the same post-covalent-BTKi pool cannot be determined ^[13]. Nurix's own Phase 2 CLL-201 draws on a narrower subset — patients who have failed a covalent BTK inhibitor, a non-covalent BTK inhibitor and a BCL-2 inhibitor ^[3]. Site geography and the breadth of prior-therapy eligibility now matter as much as the statistical plan.

Three. Build serial sequencing into the protocol before the resistance question is asked of you. The Cancer Discovery paper is titled as establishing the molecular and structural basis of pan-resistance to BTK degraders and inhibitors, and reports that its authors sequenced serial CLL samples from patients in the phase I trials; only a truncated abstract was available to Prognyx, so its findings cannot be characterised here ^[7]. If pan-resistance proves frequent, differentiation stops being degrade-versus-inhibit and becomes which resistance genotype a drug still covers — and only a trial collecting the samples can answer it.

Verdict: high threat to anyone whose CLL registrational plan is single-arm. The design window closes with the enrolment window: NCT06973187 and NCT07342478 are already recruiting against the same comparator, and CLL-306 is now enrolling toward 620 patients against a primary completion listed for October 2029 ^{[1][2][13][14]} — a package redesigned after those slots are filled has nowhere left to enrol.